Brian Stuglik, R.Ph., Chief Executive Officer
Brian Stuglik was appointed to Chief Executive Officer (CEO) of Verastem Oncology in July 2019. Mr. Stuglik is a global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in US and International pharmaceutical development, product strategy, commercialization and business development. He spent the majority of his career at Eli Lilly and Company, culminating in his role as Global Vice President and Chief Marketing Officer, Oncology Global Marketing, advancing Lilly Oncology from a single approved product to a portfolio of marketed or late-stage compounds across more than 10 cancer types. He was a founding member of Proventus Health Solutions, assisting biotech companies integrate development and commercial considerations into a unified approach. He is a member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO). Brian earned his Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Dan Paterson, President and Chief Operating Officer
Mr. Paterson joined Verastem Oncology in 2011 and has served as its Chief Operating Officer since 2014. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief Executive Officer (CEO), with specific expertise in oncology drug and diagnostic product development, business development and launch planning. Mr. Paterson was the Co-founder and COO of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding CEO of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as VP, Marketing and Corporate Development. While at PharMetrics, Mr. Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.
Rob Gagnon, Chief Business and Financial Officer
Mr. Gagnon joined Verastem Oncology as Chief Financial Officer in August 2018. Mr. Gagnon has a tremendous amount of financial and commercial experience heading global finance operations. Before joining Verastem, Mr. Gagnon was Chief Financial Officer at Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine. Prior to this, he served as Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc. as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier, he worked in a variety of senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP. Mr. Gagnon is also a member of the Boards of Directors of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.). He holds an M.B.A. from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.
Cathy Carew, Chief Organizational Effectiveness Officer
Ms. Carew has nearly 20 years of management and consulting experience in the biopharma industry, including her role at Ironwood Pharmaceuticals, where she assisted in the transition from development stage to commercial stage during a high growth period for the company. Most recently, she served as the part-time Head of Human Resources at Verastem Oncology, while also consulting with other development and clinical stage therapeutic companies, including Aquinnah Pharma, Dicerna Pharmaceuticals, Flex Pharma and OvaScience.
Earlier in her career, Ms. Carew spent more than seven years on the founding leadership team at ActivBiotics, a privately held, clinical stage company with a Phase 3 trial to evaluate rifalazil for the treatment of patients with intermittent claudication resulting from Peripheral Arterial Disease. At the same time, Ms. Carew also served as part-time Senior Director, Human Resources at Dynogen Pharmaceuticals. She has also held human resources roles at Tufts Health Plan, including spearheading a large-scale national ramp-up for its workers compensation spinoff, ManagedComp. Ms. Carew holds a B.A. in English from Union College.
Jonathan Pachter, Ph.D., Chief Scientific Officer
Dr. Pachter brings over 25 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI, he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor which progressed to Phase 3 clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab, which advanced to Phase 2 clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 50 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.
Hagop Youssoufian, MSc, M.D., Head of Medical Strategy
Prior to joining Verastem Oncology, Dr. Youssoufian served most recently as Chief Medical Officer at BIND Therapeutics. Prior to BIND, he was Executive Vice President at Progenics Pharmaceuticals and President, Research & Development and Chief Medical Officer at Ziopharm Oncology. Before joining Ziopharm, Dr. Youssoufian served as Chief Medical Officer and Senior Vice President, Global Clinical Sciences at Imclone Systems. Prior to Imclone, he served in leadership positions at Sanofi Aventis and Bristol-Myers Squibb. During his career in industry, Dr. Youssoufian was involved in the development and approval of several oncology treatments, including Sprycel®, Taxotere® and Erbitux®. Dr. Youssoufian graduated from Boston College (BS, Magna Cum Laude) and the University of Massachusetts Medical School (MSc, MD). After training in Internal Medicine at Cleveland Clinic and Johns Hopkins, he completed fellowships in Clinical Genetics at Johns Hopkins and in Hematology-Oncology at Massachusetts General Hospital, and was a Visiting Scientist at Whitehead Institute, MIT. He then served on the faculties of Harvard Medical School as Assistant Professor of Medicine and at Baylor College of Medicine as Associate Professor and Division Chief of Medical Genetics.